Analogues of a potent oxytocin antagonist with truncated c-terminus or shorter amino acid side chain of the basic amino acid at position 8

Journal of Peptide Science

Volumn 9, Issue 6, 2003, Pages 393-401

  Flouret, George ^a   Chaloin, Olivier ^a   Slaninová, Jirina ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Antagonists; Metabolites; Oxytocin; Truncated analogues

Indexed keywords

1,4 DIAMINOBUTYRIC ACID; 1,4 DIAMINOPROPIONIC ACID; ACID; AMIDE; AMINO ACID; ANTIBODY; ARGININE; BETA,BETA (3 THIAPENTAMETHYLENE BETA MERCAPTOPROPIONIC ACID); BUTYRIC ACID DERIVATIVE; DRUG METABOLITE; LYSINE; ORNITHINE; OXYTOCIN ANTAGONIST; OXYTOCIN DERIVATIVE; PEPTIDE DERIVATIVE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIDIURESIS; BABOON; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; IN VITRO STUDY; NONHUMAN; PEPTIDE SYNTHESIS; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIOIMMUNOASSAY; RAT; REVIEW;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OLIGOPEPTIDES; OXYTOCIN; PAPIO; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CONTRACTION; UTERUS;

PAPIO HAMADRYAS;

EID: 0038480007     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.471     Document Type: Review

References (50)

1. Olah KS, Gee H. The prevention of preterm delivery - can we afford to continue to ignore the cervix? Br. J. Obstet. Gynaecol. 1992; 99: 278-280.
2. Creasy RK. Preterm birth prevention: Where we are? Am. J. Obstet. Gynecol. 1993; 168: 1223-1230.
3. Radetsky P. Stopping premature births before it is too late. Science 1995; 266: 1486-1488.
4. Chibbar R, Miller FD, Mitchell BF. Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition. J. Clin. Invest. 1993; 91: 185-192.
5. Norwitz ER, Robinson JM, Challis JRG. The control of labor. N. Engl. J. Med. 1999; 341: 660-666.
6. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocrine Rev. 2000; 21: 514-550.
7. Weiss G. Endocrinology of parturition. J. Clin. Endocrinol. Metabol. 2000; 85: 4421-4425.
8. Leveno KJ, Cunningham FG. β-Adrenergic agonists for preterm labor. N. Engl. J. Med. 1992; 327: 349-351.
9. Åkerlund M, Stromberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, Melin P. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Br. J. Obstet. Gynaecol. 1987; 94: 1040-1044.
10. Melin P, Trojnar J, Johanson B, Vilhardt H, Åkerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. 1986; 111: 125-131.
11. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille J-C, Tabor B, Perry KG, Varner M, Goddwin TM, Lane R, Smith J, Shangold G, Creasy GW. An oxytocin receptor antagonist (Atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. 2000; 182: 1173-1183.
12. Freidinger RM, Bock MG, Evans BE, Pettibone DJ, Williams PD. Design of novel, nonpeptide oxytocin receptor antagonists. In Peptide Science - Present and Future, Shimonishi Y (ed.). Kluwer Academic: Dordrecht, 1999; 618-622.
13. Hruby VJ, Smith CW. Structure-activity relationships of neurohypophyseal peptides. In The Peptides, Udenfriend S, Meienhofer J. (eds), vol. 8, Chemistry, Biology and Medicine of Neurohypophyseal Hormones and their Analogs, Smith CW (ed.). Academic Press: Orlando, FL, 1987; 77-207.
14. Manning M, Cheng LL, Klis WA, Stoev SA, Przybylski J, Bankowski K, Sawyer WH, Barberis C, Chan WY. Advances in the design of selective antagonists, potential tocolytics and radioiodinated ligands for oxytocin receptors. In Oxytocin: Cellular and Molecular Approaches in Medicine and Research, Ivell R, Russell J (eds). Plenum Press: New York, 1995; 559-583.
15. Goodwin TM, Zograbyan A. Oxytocin receptor antagonists update. Emerg. Concepts Perinat. Endocrinol. 1998; 25: 859-871.
16. Manning M, Stoev S, Cheng LL, Wo NC, Chan WY. Design of oxytocin antagonists, which are more selective than Atosiban. J. Peptide Sci. 2001; 7: 449-465.
17. Flouret G, Chaloin O, Slaninová J. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8. In Peptides 2002, Benedetti E (ed.). ESCOM: Leiden; 482-483.
18. Flouret G, Chaloin O, Slaninová J. Novel bicyclic analogues of a potent oxytocin antagonist. In Peptides 2002, Benedetti E (ed.). ESCOM: Leiden; 484-485.
19. Flouret G, Majewski T, Balaspiri L, Brieher W, Mahan K, Chaloin O, Wilson L Jr, Slaninová J. Antagonists of oxytocin featuring replacement with modified β-mercapto-propionic acids at position 1. J. Peptide Sci. 2002; 8: 314-326.
20. New drug for delaying premature birth marketed. Pharmac. J. 2000; 264: 871.
21. Vavrek RJ, Ferger MF, Allen GA, Rich DH, Blomquist AT, du Vigneaud V. Synthesis of three oxytocin analogs related to [1-deaminopenicillamine]oxytocin possessing antiooxytocic activity. J. Med. Chem. 1972; 15: 123-126.
22. Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-Mercapto-β,β-pentamethylene-propionic acid]oxytocin, a potent inhibitor of oxytocin. J. Med. Chem. 1975; 18: 284-287.
23. Flouret G, Brieher W, Mahan K, Wilson L Jr. Design of potent oxytocin antagonists featuring D-tryptophan at position 2. J. Med. Chem. 1991; 34: 642-646.
24. Wilson L Jr, Parsons MT, Ouano L, Flouret G. A new tocolytic agent: development of an oxytocin antagonist for inhibiting uterine contractions. Am. J. Obstet. Gynecol. 1990; 163: 195-202.
25. Wilson L Jr, Parsons MT, Flouret G. Inhibition of spontaneous uterine contractions during the last trimester in pregnant baboons by an oxytocin antagonist. Am. J. Obstet. Gynecol. 1990; 163: 1875-1882.
26. Flouret G, Brieher W, Majewski T, Mahan K, Wilson L Jr. Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan. J. Med. Chem. 1991; 34: 2089-2094.
27. Flouret G, Brieher W, Majewski T, Wilson L Jr. Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan. Int. J. Peptide Protein Res. 1991; 38: 169-175.
28. Flouret G, Chaloin O. Tritium labeling of an oxytocin antagonist. In Peptides 2000, Martinez J, Fehrentz J-A (eds). EDK: Paris 2001; 979-980.
29. Holton P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948; 3: 328-334.
30. Merrifield RB. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963; 85: 2149-2154.
31. Stewart JM, Young JD. In Solid Phase Peptide Synthesis, 2nd edn. Pierce Chemical Co. Rockford, IL, 1984; 1-176.
32. Gisin BF. Preparation of Merrifield resins through total esterification with cesium salts. Helv. Chim. Acta 1973; 56: 1476-1482.
33. Kaiser E, Colescot RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
34. Manning M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 1968; 90: 1348-1349.
35. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc. 1953; 75: 4879-4880.
36. Sakakibara S, Shimonishi Y. A new method for releasing oxytocin from fully protected nonapeptides using anhydrous hydrogen fluoride. Bull. Chem. Soc. Jpn 1965; 38: 1412-1413.
37. Manning M, Lammek B, Kolodziejczyk AM. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin. J. Med. Chem. 1981; 24: 701-706.
38. Hope DB, Murti VVS, du Vigneaud V. A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 1962; 237: 1563-1566.
39. Manning M, Wuu TC, Baxter JWM. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 1968; 38: 396-398.
40. Bidlingmeier BA, Cohen SA, Tarvin TL. Rapid analysis of amino acids using pre-column derivatization. J. Chromatogr. 1984; 336: 93-104.
41. White WF, Hedlund MT, Rippel RH, Arnold W, Flouret G. Chemical and biological properties of gonadotropin-releasing hormone synthesized by the solid-phase method. Endocrinology 1973; 93: 96-106.
42. Munsick RA. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 1960; 66: 451-457.
43. Schild HO. pA, a new scale for the measurement of drug antagonism. Br. J. Pharmacol. 1947; 2: 189-206.
44. Vávra I, Machová A, Krejí I. Antidiuretic action of 1-deamino-8-D-arginine vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 1974; 188: 241-247.
45. Hrbas P, Barth T, Skopkova J, Lebl M, Jost K. Effect of some oxytocin analogues on natriuresis in rats. Endocrinol. Exp. 1980; 14: 151-157.
46. Debanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952; 7: 567-572.
47. Slaninová J. Fundamental biological evaluation. In Handbook of Neurohypophyseal Hormone Analogues, Jost K, Lebl M, Brtnik F (eds). CRC Press: Boca Raton, FL, 1987; Vol. 1, Part 2: 83-107.
48. Lebl A, Jost K, Brtnik F. Tables of analogs. In Handbook of Neurohypophyseal Hormone Analogues, Jost K, Lebl M, Brtnik F. (eds). CRC Press: Boca Raton, FL, 1987; Vol 2, Part 2: 127-267.
49. Roy U, Gazis D, Glass JD, Schwartz IL. Desaminopenicillamine tocinoic acid derivative - inhibitors of oxytocin. Int. J. Peptide Protein Res. 1986; 28: 154-162.
50. Slaninová J, Maletinska L, Vondrasek J, Procházka J. Magnesium and biological activity of oxytocin analogues modified on aromatic ring of amino acid in position 2. J. Peptide Sci. 2001; 7: 413-424.